Biologic response modifiers and pediatric psoriasis.
The efficacy and safety of biologic response modifiers such as etanercept, adalimumab, infliximab, and ustekinumab have been demonstrated in the treatment of psoriasis in adults, but none are currently approved for the treatment of psoriasis in children in the United States, and only etanercept is approved for the treatment of psoriasis in children in the European Union. Through case reports, case series, and a large clinical trial of the use of etanercept, the literature supports the use of these agents to treat psoriasis in children. Data on the use of the tumor necrosis factor-α antagonists etanercept, adalimumab, and infliximab in the treatment of other inflammatory diseases in children-namely Crohn's disease, juvenile arthritis, and uveitis--support their safety profile in children.
Division of Dermatology, Cincinnati Children's Hospital, Cincinnati, Ohio.
Fernanda
F
Bellodi Schmidt
Division of Dermatology, Cincinnati Children's Hospital, Cincinnati, Ohio.|Department of Dermatology, College of Medicine, University of Cincinnati, Cincinnati, Ohio.|Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio.
Kara N
KN
Shah
D000068879:Adalimumab / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002648:Child; D000068800:Etanercept / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*
D018501:Antirheumatic Agents; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept